Explore › Outcome › anxiety symptoms
Outcome

anxiety symptoms

Also known as: Clinician-rated anxiety symptoms (Hamilton Anxiety Rating Scale) HAM-A
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
PREPP (Practical Resources for Effective Postpartum Parenting)1
conditions
Education about postpartum depression1
populations
Postmenopausal Women1
studys
PMC47381661

Findings (27)

None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →

Papers (1)